Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Urology & Urologic Surgery

washington dc urology services

Request a Virtual Health Visit!
Please call (202) 741-3100 or email to schedule your virtual appointment. For more information and details, visit our virtual visits page.

The GW Medical Faculty Associates premier urology practice excels in diagnosing and treating problems involving the male and female urinary tract and the male reproductive organs. From curing cancer to restoring fertility, treating kidney stones to addressing incontinence, the urology experts deliver touches all aspects of life.

The Department of Urology is composed of multiple subspecialty trained urologists, who have additional education and training in specialized surgical techniques. Our skilled team of experts works collaboratively with other specialty areas including internal medicine, pediatrics, gynecology, geriatrics and oncology to provide highly complex care individualized to the needs of the patient.

Our Services Include:

  • Urologic oncology: urologists treat kidney cancer, bladder cancer, prostate cancer, testicular cancer, penile cancer, ureteral and renal pelvic cancers, retroperitoneal and pelvic sarcomas, Wilms' tumors, pediatric sarcomas, and other cancers.
  • Andrology: impotence and infertility. Fertility preservation and restoration, penile reconstruction, and both invasive and noninvasive therapies for erectile dysfunction are among the services offered.
  • Transition from pediatric to adult urology: Urologists expertly treat urologic conditions in children now young adults, including voiding dysfunction, reconstruction of the urinary tract, urologic cancers and correction of birth defects (congenital anomalies) of the urinary tract.
  • Endourology and stone disease: Urologists offer minimally invasive and noninvasive management of kidney/bladder stones and other urinary tract stones.
  • Neurourology and reconstructive urology. Urologists care for people who have neurologic conditions affecting the urinary system. Our urologists also offer reconstruction for people who have experienced trauma or injury of the urinary tract.
  • Men's health conditions. Urologists provide care for a wide range of conditions affecting men's health, including benign prostatic hyperplasia, voiding dysfunction, urinary incontinence, and prostate cancer screening and prevention.
  • Women's health conditions: Urologists and Advance Practitioners are board eligible and have experience in female pelvic medicine and reconstructive surgery, such as restoring urinary continence, correcting pelvic organ prolapse and treating other conditions that affect a woman's urinary tract and pelvic organs.

    Conveniently Located
    News & Information
    • DASH4DAD Race Marks Father's Day

      NBC 4 covered the Dash4Dad annual four mile race that took place on Sunday June 17, 2012 to raise funds for ZERO, The Project to End Prostate Cancer, and The GW Medical Faculty Association. Read ...

      Read Full Article

    Clinical Trials

    • Primary objective:
      To compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone.

      Secondary objectives:

      1. To compare overall survival in metastatic prostate cancer patients who received SST plus surgical excision of the primary tumor versus SST alone in the subset who specify the surgical intent stratification factor.
      2. To compare the rate of symptomatic local progression between the treatment arms.
      3. To compare progression-free survival (PFS) between the two treatment arms.
      4. To compare rates of progression-free survival between arms for the subsets of patients with and without metastasis directed therapy (MDT) to oligometastatic sites.

      Inclusion Criteria:

      1. All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate. Patients with pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. (*morphology must be consistent with SCC; synaptophysin or chromogranin positive by immunohistochemical staining is insufficient to diagnose SCC).
      2. Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g., brachytherapy, high-intensity focused ultrasound [HIFU], cryotherapy, laser ablative therapies). Any prior therapy for benign conditions, such as obstruction, are acceptable (e.g., transurethral resection of the prostate, greenlight laser ablation, microwave ablation).
      3. Patients must have evidence of metastatic disease on technetium bone scan and computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to starting standard systemic therapy. Metastatic disease that is detected by positron emission tomography (PET) scan only (sodium fluoride [NaF], prostate-specific membrane antigen [PSMA], anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid [FACBC], carbon [C]11) but not conventional imaging (technetium [Tc]99 bone scan, CT or MRI) or solitary metastases by conventional imaging, must be confirmed histologically or cytologically.
      4. Patients with known brain metastases are not eligible. Brain imaging studies are not required for eligibility if the patient has no neurologic signs or symptoms suggestive of brain metastasis. If brain imaging studies are performed, they must be negative for disease.
      5. Patients must have received no more than 28 weeks of standard systemic therapy (SST). SST is defined as current National Comprehensive Cancer Network (NCCN) guidelines for metastatic prostate cancer.
      6. Patients must not have progressed while on SST.
      7. Patients with oligometastatic prostate cancer may receive metastasis directed therapy to up to four sites of disease prior to randomization.
      8. Patients must have a complete physical examination and medical history within 28 days prior to registration.
      9. Patients must have a PSA documented prior to initiation of SST and within 28 days prior to registration. Any additional PSAs measured while receiving SST should be recorded.
      10. Patients must have a testosterone lab documented within 28 days prior to randomization. Any additional testosterone labs measured while receiving SST should be recorded as well as pretreatment initiation if available.
      11. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.
      12. Patients must be offered the opportunity to participate in translational medicine studies and specimen banking for future studies.
      13. Patients who can complete Patient-Reported Outcome instruments in English, Spanish or French, must participate in the quality of life studies.
      14. Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.